Leukapheresis in patients newly diagnosed with acute myeloid leukemia.
暂无分享,去创建一个
D. Normolle | R. Farah | A. Raptis | A. Im | K. Dorritie | M. Boyiadzis | J. Kiss | R. Redner | Seah H. Lim | V. Villgran | Jingzhou Hou | A. Sehgal | M. Agha
[1] H. Bag,et al. Leukapheresis in acute myeloid leukemia patients with hyperleukocytosis: A single center experience. , 2015, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[2] G. Ehninger,et al. How I treat hyperleukocytosis in acute myeloid leukemia. , 2015, Blood.
[3] W. Hiddemann,et al. The Role of Therapeutic Leukapheresis in Hyperleukocytotic AML , 2014, PloS one.
[4] J. Beyene,et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. , 2014, Leukemia research.
[5] T. Hervig,et al. Hyperleukocytosis and leukocytapheresis in acute leukaemias: experience from a single centre and review of the literature of leukocytapheresis in acute myeloid leukaemia , 2013, Transfusion medicine.
[6] Mark E. Williams,et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue , 2013, Journal of clinical apheresis.
[7] F. Ferrara,et al. Acute myeloid leukaemia in adults , 2013, The Lancet.
[8] P. Mintz,et al. Hyperleukocytosis, leukostasis and leukapheresis: practice management. , 2012, Blood reviews.
[9] Bob Löwenberg,et al. Review Articles (434 articles) , 2008 .
[10] E. Seifried,et al. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis , 2007, Transfusion.
[11] P. Porcu,et al. Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome. , 2007, Seminars in thrombosis and hemostasis.
[12] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] C. Bloomfield,et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.
[14] Yu Shen,et al. Leukapheresis Reduces Early Mortality in Patients with Acute Myeloid Leukemia with High White Cell Counts But Does Not Improve Long Term Survival , 2001, Leukemia & lymphoma.
[15] M. Slovak,et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study , 2000 .
[16] X. Thomas,et al. Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis , 2000, Annals of Hematology.
[17] N. Heerema,et al. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate , 1997, British journal of haematology.